BPI fold containing family B member 4Genealiases: C20orf186 · LPLUNC4 · RY2G5 · dJ726C3.5
Q-omics provides the consensus-scored BPIFB4 profile across patient tissues and cancer cell-line models. BPIFB4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BPIFB4 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, BPIFB4 RNA expression shows 7,800 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where BPIFB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFB4 survival associations across molecular data types. BPIFB4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFB4 RNA expression–survival associations across cancer types. High BPIFB4 expression shows unfavorable associations in KIRC, LIHC, THYM and OV, but favorable associations in PAAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BPIFB4 RNA expression.
This table summarizes BPIFB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BPIFB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFB4 shows higher tumor expression in LUAD, LUSC and LIHC. The LUAD box plot shows higher BPIFB4 RNA expression in tumor versus normal tissue (log2 FC = +0.448, t-test p = .003).
This table shows molecular features associated with BPIFB4 in patient tissues and cancer cell lines. In patient samples, BPIFB4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
